BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8633088)

  • 1. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.
    James G; Goldstein JL; Brown MS
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4454-8. PubMed ID: 8633088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.
    James GL; Goldstein JL; Brown MS
    J Biol Chem; 1995 Mar; 270(11):6221-6. PubMed ID: 7890759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-Ras-transformed Rat-1 cells, but not in untransformed cells.
    James GL; Brown MS; Cobb MH; Goldstein JL
    J Biol Chem; 1994 Nov; 269(44):27705-14. PubMed ID: 7961691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
    Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
    J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of the Ras-induced transformed phenotype by HR12, a novel ras farnesylation inhibitor, is mediated by the Mek/Erk pathway.
    Reuveni H; Geiger T; Geiger B; Levitzki A
    J Cell Biol; 2000 Dec; 151(6):1179-92. PubMed ID: 11121434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesyl protein transferase inhibitor BZA-5B blocks farnesylation of nuclear lamins and p21ras but does not affect their function or localization.
    Dalton MB; Fantle KS; Bechtold HA; DeMaio L; Evans RM; Krystosek A; Sinensky M
    Cancer Res; 1995 Aug; 55(15):3295-304. PubMed ID: 7614464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell line.
    Fokstuen T; Rabo YB; Zhou JN; Karlson J; Platz A; Shoshan MC; Hansson J; Linder S
    Anticancer Res; 1997; 17(4A):2347-52. PubMed ID: 9252645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
    Lerner EC; Qian Y; Blaskovich MA; Fossum RD; Vogt A; Sun J; Cox AD; Der CJ; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26802-6. PubMed ID: 7592920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
    Lebowitz PF; Davide JP; Prendergast GC
    Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.
    James GL; Goldstein JL; Brown MS; Rawson TE; Somers TC; McDowell RS; Crowley CW; Lucas BK; Levinson AD; Marsters JC
    Science; 1993 Jun; 260(5116):1937-42. PubMed ID: 8316834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action.
    Karlson J; Borg-Karlson AK; Unelius R; Shoshan MC; Wilking N; Ringborg U; Linder S
    Anticancer Drugs; 1996 Jun; 7(4):422-9. PubMed ID: 8826611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
    Prendergast GC; Davide JP; deSolms SJ; Giuliani EA; Graham SL; Gibbs JB; Oliff A; Kohl NE
    Mol Cell Biol; 1994 Jun; 14(6):4193-202. PubMed ID: 8196657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent inhibition of protein farnesyltransferase by a benzodiazepine peptide mimetic.
    Roskoski R; Ritchie PA
    Biochemistry; 2001 Aug; 40(31):9329-35. PubMed ID: 11478901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disrupting the transforming activity of shrimp ras(Q(61)K) by deleting the CAAX box at the C-terminus.
    Huang CF; Chen CH; Chuang NN
    J Exp Zool; 2001 Jun; 289(7):441-8. PubMed ID: 11351331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.